vs
CYTOKINETICS INC（CYTK）与Digimarc CORP（DMRC）财务数据对比。点击上方公司名可切换其他公司
CYTOKINETICS INC的季度营收约是Digimarc CORP的2.0倍（$17.8M vs $8.9M），Digimarc CORP净利率更高（-47.2% vs -1030.9%，领先983.6%），CYTOKINETICS INC同比增速更快（4.9% vs 2.9%），Digimarc CORP自由现金流更多（$895.0K vs $-148.3M）
Cytokinetics是一家总部位于美国加利福尼亚州南旧金山的生物制药企业，专注于研发肌肉激活剂与肌肉抑制剂类候选药物，用于治疗以肌肉功能受损或衰退为典型特征的各类疾病，为相关患者提供潜在创新治疗方案。
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
CYTK vs DMRC — 直观对比
营收规模更大
CYTK
是对方的2.0倍
$8.9M
营收增速更快
CYTK
高出2.0%
2.9%
净利率更高
DMRC
高出983.6%
-1030.9%
自由现金流更多
DMRC
多$149.2M
$-148.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.8M | $8.9M |
| 净利润 | $-183.0M | $-4.2M |
| 毛利率 | — | 63.5% |
| 营业利润率 | -1004.6% | -48.2% |
| 净利率 | -1030.9% | -47.2% |
| 营收同比 | 4.9% | 2.9% |
| 净利润同比 | -22.0% | 51.4% |
| 每股收益（稀释后） | $-1.51 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CYTKDMRC
| Q4 25 | $17.8M | $8.9M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $66.8M | $8.0M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | $16.9M | $8.7M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $10.4M | ||
| Q1 24 | — | $9.9M |
净利润CYTKDMRC
| Q4 25 | $-183.0M | $-4.2M | ||
| Q3 25 | — | $-8.2M | ||
| Q2 25 | $-134.4M | $-8.2M | ||
| Q1 25 | — | $-11.7M | ||
| Q4 24 | $-150.0M | $-8.6M | ||
| Q3 24 | — | $-10.8M | ||
| Q2 24 | — | $-9.3M | ||
| Q1 24 | — | $-10.3M |
毛利率CYTKDMRC
| Q4 25 | — | 63.5% | ||
| Q3 25 | — | 58.3% | ||
| Q2 25 | — | 58.8% | ||
| Q1 25 | — | 65.0% | ||
| Q4 24 | — | 60.8% | ||
| Q3 24 | — | 62.4% | ||
| Q2 24 | — | 66.1% | ||
| Q1 24 | — | 62.5% |
营业利润率CYTKDMRC
| Q4 25 | -1004.6% | -48.2% | ||
| Q3 25 | — | -109.7% | ||
| Q2 25 | -167.0% | -105.2% | ||
| Q1 25 | — | -128.9% | ||
| Q4 24 | -821.4% | -105.1% | ||
| Q3 24 | — | -120.4% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -109.2% |
净利率CYTKDMRC
| Q4 25 | -1030.9% | -47.2% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | -201.2% | -102.6% | ||
| Q1 25 | — | -125.2% | ||
| Q4 24 | -886.3% | -99.9% | ||
| Q3 24 | — | -113.9% | ||
| Q2 24 | — | -89.3% | ||
| Q1 24 | — | -104.0% |
每股收益（稀释后）CYTKDMRC
| Q4 25 | $-1.51 | $-0.18 | ||
| Q3 25 | — | $-0.38 | ||
| Q2 25 | $-1.12 | $-0.38 | ||
| Q1 25 | — | $-0.55 | ||
| Q4 24 | $-1.26 | $-0.40 | ||
| Q3 24 | — | $-0.50 | ||
| Q2 24 | — | $-0.43 | ||
| Q1 24 | — | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $122.5M | $12.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-659.6M | $40.2M |
| 总资产 | $1.4B | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CYTKDMRC
| Q4 25 | $122.5M | $12.9M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | $74.9M | $16.1M | ||
| Q1 25 | — | $21.6M | ||
| Q4 24 | $94.9M | $28.7M | ||
| Q3 24 | — | $33.7M | ||
| Q2 24 | — | $41.5M | ||
| Q1 24 | — | $48.9M |
总债务CYTKDMRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $609.7M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $619.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CYTKDMRC
| Q4 25 | $-659.6M | $40.2M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | $-368.7M | $46.5M | ||
| Q1 25 | — | $50.0M | ||
| Q4 24 | $-135.4M | $61.4M | ||
| Q3 24 | — | $70.2M | ||
| Q2 24 | — | $77.2M | ||
| Q1 24 | — | $84.5M |
总资产CYTKDMRC
| Q4 25 | $1.4B | $53.0M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | $1.2B | $60.7M | ||
| Q1 25 | — | $66.5M | ||
| Q4 24 | $1.4B | $75.8M | ||
| Q3 24 | — | $85.0M | ||
| Q2 24 | — | $93.4M | ||
| Q1 24 | — | $99.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-142.7M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | $-148.3M | $895.0K |
| 自由现金流率自由现金流/营收 | -835.2% | 10.0% |
| 资本支出强度资本支出/营收 | 31.8% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-438.9M | $-12.3M |
8季度趋势，按日历期对齐
经营现金流CYTKDMRC
| Q4 25 | $-142.7M | $991.0K | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | $-128.2M | $-4.7M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | $-65.6M | $-4.2M | ||
| Q3 24 | — | $-7.1M | ||
| Q2 24 | — | $-6.8M | ||
| Q1 24 | — | $-8.4M |
自由现金流CYTKDMRC
| Q4 25 | $-148.3M | $895.0K | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | $-132.4M | $-4.9M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | $-66.9M | $-4.2M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | — | $-6.9M | ||
| Q1 24 | — | $-8.5M |
自由现金流率CYTKDMRC
| Q4 25 | -835.2% | 10.0% | ||
| Q3 25 | — | -36.9% | ||
| Q2 25 | -198.3% | -61.0% | ||
| Q1 25 | — | -59.1% | ||
| Q4 24 | -395.0% | -49.1% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | — | -66.1% | ||
| Q1 24 | — | -85.8% |
资本支出强度CYTKDMRC
| Q4 25 | 31.8% | 1.1% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | 6.2% | 2.5% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 7.6% | 0.2% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CYTK
| Other | $9.1M | 51% |
| Collaboration Revenues | $8.7M | 49% |
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
